1-4 of 4
Keywords: BRAF
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Biochem Soc Trans (2021) 49 (1): 237–251.
Published: 24 December 2020
...Frazer A. Cook; Simon J. Cook The RAS-regulated RAF–MEK1/2–ERK1/2 pathway promotes cell proliferation and survival and RAS and BRAF proteins are commonly mutated in cancer. This has fuelled the development of small molecule kinase inhibitors including ATP-competitive RAF inhibitors. Type I and type...
Biochem Soc Trans (2014) 42 (4): 776–783.
Published: 11 August 2014
...Matthew J. Sale; Simon J. Cook Recent clinical data with BRAF and MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors have demonstrated the remarkable potential of targeting the RAF–MEK1/2–ERK1/2 signalling cascade for the treatment...
Biochem Soc Trans (2014) 42 (4): 727–732.
Published: 11 August 2014
...Claudia Wellbrock The serine threonine kinases BRAF and MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] are major regulators of the ERK/MAPK pathway, which is deregulated in the majority of melanomas. Targeting BRAF is an effective therapy...
Biochem Soc Trans (2007) 35 (5): 1329–1333.
Published: 25 October 2007
...C. Pritchard; L. Carragher; V. Aldridge; S. Giblett; H. Jin; C. Foster; C. Andreadi; T. Kamata Oncogenic mutations in the BRAF gene are detected in ∼7% of human cancer samples with a particularly high frequency of mutation in malignant melanomas. Over 40 different missense BRAF mutations have been...